APO-ACYCLOVIR TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

ACYCLOVIR

متاح من:

APOTEX INC

ATC رمز:

J05AB01

INN (الاسم الدولي):

ACYCLOVIR

جرعة:

200MG

الشكل الصيدلاني:

TABLET

تركيب:

ACYCLOVIR 200MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

100/500

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

NUCLEOSIDES AND NUCLEOTIDES

ملخص المنتج:

Active ingredient group (AIG) number: 0115506002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

1997-08-21

خصائص المنتج

_____________________________________________________________________________________
_APO-ACYCLOVIR Product Monograph _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
APO-ACYCLOVIR
ACYCLOVIR TABLETS
APOTEX STANDARD
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
APOTEX INC. DATE OF PREPARATION:
150 SIGNET DRIVE
April 10, 1997
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
August 31, 2021
Control No. 255331
_____________________________________________________________________________________
_APO-ACYCLOVIR Tablets Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
6
DRUG INTERACTIONS
..........................................................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................................................
9
OVERDOSAGE
......................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................